FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

27 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-12-02

Study Completion Date

2025-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a phase II, open-label, non-randomized study in subjects with histologically confirmed diagnosis of left-sided RAS WT advanced adenocarcinoma of the colon or rectum who have not received prior systemic therapy for metastatic disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

NCT01226719

Colorectal Cancer

COMPLETED PHASE2

Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer

NCT00508404

Metastatic Colorectal Cancer

COMPLETED PHASE2

Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal

NCT03751176

Colorectal Cancer Metastatic

UNKNOWN PHASE2

Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer

NCT00101894

Rectal Cancer Colon Cancer

COMPLETED PHASE1

Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer

NCT03635021

Colorectal Cancer

ACTIVE_NOT_RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This trial is designed to evaluate the efficacy of the combination of FOLFOXIRI and panitumumab as first-line therapy in patients with metastatic, left-sided, RAS WT CRC. The research hypothesis is that in this cohort of patients, the combination of triplet chemotherapy and anti-EGFR therapy will confer higher response rates and efficacy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Cancer Metastatic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Multicenter open-label

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active

This is an open label study single arm

Group Type OTHER

Oxaliplatin

Intervention Type DRUG

2 week cycles

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Oxaliplatin

2 week cycles

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Irinotecan Leucovorin Panitumumab

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subjects must have signed an approved informed consent.
2. Histologically confirmed diagnosis of advanced adenocarcinoma of the colon or rectum.
3. No previous systemic chemotherapy for metastatic disease

* Subjects who have had prior adjuvant chemotherapy for non-metastatic disease are eligible if more than six months have elapsed after completing therapy
* Subjects treated with adjuvant chemotherapy who relapse within six months after completion will not be eligible.
4. Bidimensionally measurable disease as defined in Section 3.3.1.
5. RAS wild-type tested in

* KRAS exon 2 (codons 12/13)
* KRAS exon 3 (codons 59/61)
* KRAS exon 4 (codons 117/146)
* NRAS exon 2 (codons 12/13)
* NRAS exon 3 (codons 59/61)
* NRAS exon 4 (codons 117/146)
6. ECOG Performance Status 0-1 (Appendix 1).
7. Recovery in full, from any previous surgical procedure.
8. Subjects \>=18 years of age. Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 6 months after the study in such a manner that the risk of pregnancy is minimized.

WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not postmenopausal.

WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours prior to the start of study medication.
9. Creatinine clearance ≥ 50 ml/min or serum creatinine ≤ 1.5 x upper limit of normal.
10. Bilirubin ≤ 1.5 x upper limit of normal
11. AST, ALT ≤ 2.5 x upper limit of normal in absence of liver metastases, or ≤ 5 x upper limit of normal in presence of liver metastases,
12. Albumin within normal institutional limits
13. Magnesium ≥ lower limit of normal; calcium ≥ lower limit of normal .
14. Absolute Neutrophil Count \> 1500/mm3 and platelets \> 100,000/mm3.

Exclusion Criteria

1. WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 6 months after the study. Subjects who are men must also agree to use effective contraception.
2. Women who are pregnant or breastfeeding.
3. Women with a positive pregnancy test on enrollment or prior to study drug administration.
4. Subjects with \>grade 1 neuropathy except for loss of tendon reflex.
5. Any active or uncontrolled infection.
6. Clinically significant cardiovascular disease (myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) ≤ 6 months before enrollment
7. Past or current history of malignancies except for the indication under this study and curatively treated:

* Basal and squamous cell carcinoma of the skin
* In-situ carcinoma of the cervix
* Other malignant disease without recurrence after at least 3 years of follow-up
8. History or evidence upon physical examination of CNS disease unless adequately treated (e.g. primary brain tumor, seizure not controlled with standard medical therapy, brain metastases or history of stroke).
9. Clinically relevant interstitial lung disease (pneumonitis, pulmonary fibrosis, evidence of interstitial lung disease on baseline chest CT scan)
10. Allogeneic transplantation requiring immunosuppressive therapy.
11. Severe non-healing wounds, ulcers or bone fractures.
12. Evidence of bleeding diathesis or coagulopathy.
13. Patients not receiving therapeutic anticoagulation must have an INR \< 1.5 x ULN and aPTT \< 1.5 x ULN within 7 days prior to randomization. The use of full-dose anticoagulants is allowed as long as the INR or aPTT is within therapeutic limits (according to the medical standard in the institution) and the patient has been on a stable dose for anticoagulants for at least two weeks.
14. Concomitant therapy with certain anti-viral medicines (sorivudine and brivudine or analogue compounds).
15. Major surgical procedure, open biopsy, nor significant traumatic injury within 28 days prior to study treatment start, or anticipation of the need for major surgical procedure during the course of the study except for surgery for colorectal cancer with curative intent and central venous line placement for chemotherapy administration.
16. Subjects with known allergy to the study drugs or to any of its metabolites.
17. Known DPD deficiency.
18. Current or recent (within the 28 days prior to starting study treatment) treatment of another investigational drug or participation in another investigational study.
19. Known grade III/IV allergic reaction against monoclonal antibodies.
20. Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the subject before registration in the trial.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No